---
title: "Scientific Industries, Inc. | 10-Q: FY2025 Q3 Revenue: USD 1.404 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/266626838.md"
datetime: "2025-11-19T22:24:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/266626838.md)
  - [en](https://longbridge.com/en/news/266626838.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/266626838.md)
---

# Scientific Industries, Inc. | 10-Q: FY2025 Q3 Revenue: USD 1.404 M

Revenue: As of FY2025 Q3, the actual value is USD 1.404 M.

EPS: As of FY2025 Q3, the actual value is USD 0.34.

EBIT: As of FY2025 Q3, the actual value is USD -1.545 M.

### Segment Revenue

-   **Benchtop Laboratory Equipment**: Revenue for the three months ended September 30, 2025, was $1,068,300, an increase from $881,900 in the same period in 2024. For the nine months ended September 30, 2025, revenue was $2,734,300, up from $2,380,600 in 2024.
-   **Bioprocessing Systems**: Revenue for the three months ended September 30, 2025, was $335,700, down from $452,500 in the same period in 2024. For the nine months ended September 30, 2025, revenue was $692,800, down from $1,134,000 in 2024.

### Operational Metrics

-   **Loss from Operations**: For the three months ended September 30, 2025, the loss from operations was $1,522,300, compared to $1,565,800 in 2024. For the nine months ended September 30, 2025, the loss was $5,434,700, compared to $5,685,800 in 2024.
-   **Gross Profit**: The gross profit percentage for the three months ended September 30, 2025, was 45.5%, down from 51.0% in 2024. For the nine months ended September 30, 2025, it was 39.8%, down from 44.1% in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: For the nine months ended September 30, 2025, net cash used in operating activities was - $4,390,700, compared to - $4,186,000 in 2024.
-   **Net Cash Provided by Investing Activities**: For the nine months ended September 30, 2025, net cash provided by investing activities was $2,444,300, compared to $2,429,900 in 2024.

### Unique Metrics

-   **Gain on Sale of Genie Product Line**: The company recorded a gain of $5,263,400 from the sale of the Genie product line in August 2025.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to focus on the Bioprocessing Systems Operations, despite the current start-up stage and ongoing cash outflows. The sale of the Genie product line is expected to provide sufficient cash flow for at least one year.
-   **Non-Core Business**: The company completed the sale of its Genie Division, which is expected to streamline operations and focus resources on core business areas.

### Related Stocks

- [SCND.US](https://longbridge.com/en/quote/SCND.US.md)

## Related News & Research

- [Why VOO ETF Investors Don't Have to Worry About Buying SpaceX Stock Just Yet](https://longbridge.com/en/news/289506372.md)
- [Nvidia or Palantir: Top Investor Says Only One AI Stock Is a Strong Buy](https://longbridge.com/en/news/289524885.md)
- [Intel's stock could push even higher thanks to this subtle dynamic, BofA says](https://longbridge.com/en/news/289498064.md)
- [Microsoft Just Gave Investors 3 Dates They Can't Afford to Ignore](https://longbridge.com/en/news/289500746.md)
- [Oracle's stock is seeing its worst run in a quarter-century as this key AI debate rages on](https://longbridge.com/en/news/289491717.md)